Guo Huang

Guo Huang


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2004 in Transplantation
Verified
Journal Article
Closed access
GHGuo Huang
Guo Huang
MZMin Zhao
Min Zhao
PJPeter Martin Jones
Peter Martin Jones
SPShanta J. Jean Persaud
Shanta J. Jean Persaud
RRReshma Ramracheya
Reshma Ramracheya
SAStephanie Amiel
Stephanie Amiel
Successful islet transplantation is dependent on the quality and quantity of islets infused. Islets are purified on density gradients, but procedures currently used have limited capacity for pancreatic digests, islet yield, and viability. We aimed to improve islet purification with a modified gradient medium. Biocoll was diluted in University of Wisconsin solution to create linear density gradients of 1.065 to 1.095 g/mL. Properties of islets purified from 22 human pancreas digests with modified medium were compared with 15 preparations using standard medium. The modification increased the capacity of gradients for pancreatic digests from 20 to 60 mL, islet yield increased from 218,000 to 435,318 per isolation, and viability increased from 65.4% to 92.1%. Islet fractions contained greater than 95% of recovered insulin. Islets showed good physiologic responses to secretagogues and restored normoglycemia in streptozotocin-induced diabetic severe combined immunodeficiency disease mice. The new medium enhances yield, purity, and viability of human islet preparations for clinical islet transplantation.

20 September 2007 in Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
MZMin Zhao
Min Zhao
SAStephanie A Amiel
Stephanie A Amiel
MCMichael R Christie
Michael R Christie
Paolo MuiesanPaolo Muiesan
Paolo Muiesan
PSParthi Srinivasan
Parthi Srinivasan
GHGuo Huang
Guo Huang
The origin of cells replacing ageing β-cells in adult life is unknown. This study assessed the expression of classic stem cell markers: Oct4, Sox2 and CD34 in islet-enriched fractions versus exocrine cell-enriched fractions from 25 adult human pancreases following human islet isolation. Expression of Oct4, Sox2 and CD34 mRNAs was found in all cell samples, with no significant differences between endocrine and exocrine cell fractions. Immunohistochemical staining for Oct4, Sox2, CD133, CD34, CK19, insulin and nestin on human pancreas sections showed that the majority of Oct4+ve cells were found in the walls of small ducts. Similar localisations were observed for Sox2+ve cells. The majority of Sox2+ve cells were found to co-express Oct4 proteins, but not vice versa. Cells positive for Oct4 and Sox2 appeared to be a unique cell population in the adult human pancreases without co-expression for CK19, CD34, CD133, insulin and nestin proteins. The numbers of Oct4+ve and Sox2+ve cells varied among donors and were ∼1–200 and 1–30 per 100 000 pancreatic cells respectively.

16 July 2008 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MZMin Zhao
Min Zhao
SAStephanie A. Amiel
Stephanie A. Amiel
SASanaz Ajami
Sanaz Ajami
JJJie Jiang
Jie Jiang
MRMohamed Rela
Mohamed Rela
GHGuo Huang
Guo Huang
Pluri-potent bone marrow stromal cells (MSCs) provide an attractive opportunity to generate unlimited glucose-responsive insulin-producing cells for the treatment of diabetes. We explored the potential for human MSCs (hMSCs) to be differentiated into glucose-responsive cells through a non-viral genetic reprogramming approach. Two hMSC lines were transfected with three genes: PDX-1, NeuroD1 and Ngn3 without subsequent selection, followed by differentiation induction in vitro and transplantation into diabetic mice. Human MSCs expressed mRNAs of the archetypal stem cell markers: Sox2, Oct4, Nanog and CD34, and the endocrine cell markers: PDX-1, NeuroD1, Ngn3, and Nkx6.1. Following gene transfection and differentiation induction, hMSCs expressed insulin in vitro, but were not glucose regulated. After transplantation, hMSCs differentiated further and ∼12.5% of the grafted cells expressed insulin. The graft bearing kidneys contained mRNA of insulin and other key genes required for the functions of beta cells. Mice transplanted with manipulated hMSCs showed reduced blood glucose levels (from 18.9+/−0.75 to 7.63+/−1.63 mM). 13 of the 16 mice became normoglycaemic (6.9+/−0.64 mM), despite the failure to detect the expression of SUR1, a K+-ATP channel component required for regulation of insulin secretion. Our data confirm that hMSCs can be induced to express insulin sufficient to reduce blood glucose in a diabetic mouse model. Our triple gene approach has created cells that seem less glucose responsive in vitro but which become more efficient after transplantation. The maturation process requires further study, particularly the in vivo factors influencing the differentiation, in order to scale up for clinical purposes.

31 August 2007 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MZM. Zhao
M. Zhao
Paolo MuiesanPaolo Muiesan
Paolo Muiesan
SAS. A. Amiel
S. A. Amiel
PSP. Srinivasan
P. Srinivasan
HAH. Asare‐Anane
H. Asare‐Anane
GHGuo Huang
Guo Huang
Islets from brain‐dead donors (BDDs) are being used in the treatment of Type 1 diabetes. However, both donor numbers and islet survival are limited. We explored the clinical potential for islets from non‐heart‐beating donors (NHBDs), who have lower circulating cytokines, by comparing islets from 10 NHBDs against 12 identically‐isolated islets from BDDs over the same time period. The quantity and quality of islets from NHBDs was good. NHBD yielded ∼12.6% more islets than those of BDDs (505 000 ± 84 230 vs. 400 970 ± 172 430 islet equivalent number [IEQ]/pancreas, p = 0.01) with comparable viability. ATP and GTP contents were lower (6.026 ± 3.076 vs. 18.105 ± 7.8 nM/mg protein, p = 0.01 and 1.52 ± 0.87 vs. 3.378 ± 0.83 nM/mg protein, p = 0.04) and correlated negatively to warm ischemia time (R2= 0.8022 and R2= 0.7996, respectively). Islets from NHBDs took longer to control hyperglycemia in diabetic mice, but were equally able to sustain euglycemia. With a warm ischemia time (WIT) of ≤25 min, islets from NHBDs are at least as competent as islets from BDDs and should be suitable for clinical use.

17 August 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
MZM. Zhao
M. Zhao
SAS. A. Amiel
S. A. Amiel
MCM. R. Christie
M. R. Christie
MRM. Rela
M. Rela
NHN. Heaton
N. Heaton
GHGuo Huang
Guo Huang